查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1563974

全球骨髓移植市场

Bone Marrow Transplant
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2030年全球骨髓移植市场将达147亿美元

2023年全球骨髓移植市场预计为111亿美元，预计到2030年将达到147亿美元，2023-2030年分析期间复合年增长率为4.1%。骨髓瘤适应症是本报告分析的细分市场之一，预计复合年增长率为 4.1%，到分析期结束时将达到 48 亿美元。分析期间，白血病适应症细分市场的复合年增长率预计为 4.4%。

美国市场预估29亿美元，中国预期复合年增长率6.3%

预计2023年美国骨髓移植市场规模将达29亿美元。中国作为世界第二大经济体，预计2030年市场规模将达31亿美元，2023-2030年分析期间复合年增长率为6.3%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 2.7% 和 3.3%。在欧洲，德国的复合年增长率预计为 3.2%。

全球骨髓移植市场－主要趋势与驱动因素总结

骨髓移植如何挽救生命以及为什么它很重要？

骨髓移植（BMT）是一种紧急医疗程序，在治疗各种危及生命的疾病，特别是白血病、淋巴瘤和多发性骨髓瘤等血癌方面发挥着至关重要的作用。这种治疗方法以健康的干细胞取代受损或患病的骨髓，使血液和免疫系统再生，并为患者提供第二次生命机会。骨髓移植包括自体骨髓移植和同种异体骨髓移植，自体骨髓移植是采集患者自身的干细胞，经过处理后返回体内，而同种异体骨髓移植是从亲属或无关的捐赠者提供干细胞。这些方法之间的选择取决于患者的病情、合适的捐赠者的可用性以及所治疗的特定疾病。除了在癌症治疗中发挥重要作用外，BMT 还用于治疗严重的血液疾病，如镰状细胞疾病和地中海贫血。这种治疗方法正在彻底改变血液学领域，并为先前治疗选择有限的患者带来希望。

骨髓移植的进展和技术如何？

多年来骨髓移植技术的进步显着改善了患者的治疗效果并扩大了可治疗疾病的范围。主要创新之一是 RIC（低强度调节）植入的发展。这使得老年患者和患有其他健康问题的患者能够接受较低剂量的化疗和放射线治疗的骨髓移植。这种方法降低了与传统高剂量预处理方案相关的风险，并允许更多患者接受 BMT。另一个重要的进步是半相合移植的使用，其中供体与受体仅半匹配。这项技术大大增加了潜在捐赠者的数量，使患者更容易找到匹配的捐赠者，特别是在完美匹配很少见的不同种族人群中。此外，週边血干细胞和脐带血等干细胞采集方法的改进增加了可用干细胞来源的数量，每种干细胞来源在植入速度和免疫恢復方面都具有优势。这些技术进步提高了骨髓移植的有效性、安全性和可近性。

骨髓移植有哪些挑战和併发症？

儘管骨髓移植具有挽救生命的潜力，但该手术并非没有重大挑战和风险。最严重的併发症之一是移植物抗宿主疾病（GVHD），这是一种危及生命的疾病，当捐赠的干细胞攻击接受者的身体时，会影响皮肤、肝臟和胃肠道，这是一种潜在威胁的疾病。免疫抑制治疗和移植后护理的进步有助于控制和降低 GVHD 的严重程度，但它仍然是一个主要问题，特别是在同种异体移植中。另一个问题是移植后免疫恢復期间感染的高风险。这是因为患者由于免疫系统受到抑製而极其脆弱。预防性抗生素和抗病毒药物的开发改善了感染控制，但需要密切注意和监测。此外，骨髓移植的成功很大程度上取决于捐赠者和受体的兼容性，找到合适的匹配可能很困难，特别是对于少数族裔患者而言。最后，该手术费用昂贵且资源密集，限制了全世界许多患者的使用，特别是在资源匮乏的环境中。解决这些挑战对于提高骨髓移植的整体成功率和可近性至关重要。

骨髓移植市场扩大的驱动力是什么？

骨髓移植市场的成长是由反映医疗技术进步和医疗保健需求变化的多个因素所推动的。血癌和其他血液疾病的盛行率不断增加，增加了对骨髓移植作为治疗选择的需求。技术进步，例如改进的配对技术和扩大的捐赠者登记册，使找到相容的捐赠者变得更容易，并提高了移植的可用性和成功率。个人化医疗的兴起也推动了这个市场的成长，它可以根据每个患者的基因特征来客製化治疗方案，从而实现更精确的匹配和更好的治疗结果。此外，人口老化也有助于市场扩张。这是因为，由于降低强度训练等技术的进步，患有骨髓发育不良症候群等疾病的老年人越来越多地接受移植。此外，人们对捐赠者登记重要性的认识不断提高以及公共和私人脐带血库的扩张正在增加干细胞的可用性，并使更多患者更容易获得移植。最后，医疗保健支出和研发投资的增加正在刺激该行业的创新，进一步推动市场成长并改善患者的治疗结果。

受访企业范例（38家知名企业）

  • Allcells LLC
  • American Type Culture Collection（ATCC）
  • Beike Biotechnology Co., Ltd.
  • BioTime, Inc.
  • Cellular Dynamics International
  • Corestem, Inc.
  • Gamida Cell Ltd.
  • HemaCare Corporation
  • Lifeline Cell Technology
  • Lonza Group Ltd.
  • Mesoblast Ltd.
  • Promocell GmbH
  • ReachBio LLC
  • Sanofi-aventis US LLC

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 比赛

简介目录
Product Code: MCP10772

Global Bone Marrow Transplant Market to Reach US$14.7 Billion by 2030

The global market for Bone Marrow Transplant estimated at US$11.1 Billion in the year 2023, is expected to reach US$14.7 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2023-2030. Myeloma Indication, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Leukemia Indication segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.9 Billion While China is Forecast to Grow at 6.3% CAGR

The Bone Marrow Transplant market in the U.S. is estimated at US$2.9 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.1 Billion by the year 2030 trailing a CAGR of 6.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Bone Marrow Transplant Market - Key Trends and Drivers Summarized

How Does Bone Marrow Transplant Save Lives and Why Is It Crucial?

Bone marrow transplant (BMT) is a life-saving medical procedure that plays a pivotal role in the treatment of various life-threatening diseases, particularly blood cancers such as leukemia, lymphoma, and multiple myeloma. The procedure involves replacing damaged or diseased bone marrow with healthy stem cells, which can regenerate the blood and immune system, offering patients a second chance at life. There are two main types of bone marrow transplants: autologous, where the patient’s own stem cells are harvested, treated, and then returned to their body, and allogeneic, where the stem cells are donated by another person, often a relative or a matched unrelated donor. The choice between these methods depends on the patient’s condition, the availability of a suitable donor, and the specific disease being treated. BMT is not only essential for treating cancer but is also used to manage severe blood disorders such as aplastic anemia and genetic conditions like sickle cell disease and thalassemia. This procedure has been transformative in the field of hematology, offering hope to patients who once had limited treatment options.

What Are the Advancements and Techniques in Bone Marrow Transplantation?

Over the years, advancements in bone marrow transplantation techniques have significantly improved patient outcomes and expanded the range of treatable conditions. One of the major innovations is the development of reduced-intensity conditioning (RIC) transplants, which allow older patients or those with other health issues to undergo the procedure with lower doses of chemotherapy and radiation. This approach has made BMT accessible to a broader patient population, reducing the risks associated with traditional high-dose conditioning regimens. Another significant advancement is the use of haploidentical transplants, where a donor is only a half-match to the recipient. This technique has greatly increased the pool of potential donors, making it easier for patients to find a match, particularly in ethnically diverse populations where full matches may be rare. Additionally, improvements in stem cell harvesting, including the use of peripheral blood stem cells and cord blood, have provided more options for stem cell sources, each with its own set of benefits in terms of engraftment speed and immune recovery. These technological advancements have collectively enhanced the effectiveness, safety, and accessibility of bone marrow transplants.

What Challenges and Complications Are Associated with Bone Marrow Transplants?

Despite the life-saving potential of bone marrow transplants, the procedure is not without significant challenges and risks. One of the most serious complications is graft-versus-host disease (GVHD), which occurs when the donated stem cells attack the recipient’s body, leading to potentially life-threatening conditions affecting the skin, liver, and gastrointestinal tract. Advances in immunosuppressive therapies and post-transplant care have helped to manage and mitigate the severity of GVHD, but it remains a major concern, particularly in allogeneic transplants. Another challenge is the high risk of infection during the period of immune recovery post-transplant, as patients are extremely vulnerable due to the suppression of their immune systems. The development of prophylactic antibiotics and antiviral drugs has improved infection control, but it requires meticulous care and monitoring. Additionally, the success of a bone marrow transplant heavily depends on the compatibility between donor and recipient, and finding a suitable match can be difficult, especially for patients from minority ethnic backgrounds. Lastly, the procedure is expensive and resource-intensive, limiting access for many patients globally, especially in low-resource settings. Addressing these challenges is critical to improving the overall success rates and accessibility of bone marrow transplants.

What’s Fueling the Expansion of the Bone Marrow Transplant Market?

The growth in the bone marrow transplant market is driven by several factors that reflect advancements in medical technology and changing healthcare demands. The increasing prevalence of blood cancers and other hematological disorders has led to a higher demand for bone marrow transplants as a treatment option. Technological advancements, such as the development of improved matching techniques and the expansion of donor registries, have made it easier to find compatible donors, increasing the availability and success rates of transplants. The rise of personalized medicine, which tailors treatments to the genetic profile of individual patients, is also driving growth in this market, as it enables more precise matching and better outcomes. Moreover, the aging population is contributing to the market expansion, as older adults with conditions like myelodysplastic syndromes are increasingly undergoing transplants thanks to advancements like reduced-intensity conditioning. Additionally, growing awareness of the importance of donor registration and the expansion of public and private cord blood banks are increasing the availability of stem cells, making transplants more accessible to a wider patient population. Finally, increased healthcare spending and investment in research and development are fueling innovation in this field, further propelling market growth and improving patient outcomes.

Select Competitors (Total 38 Featured) -

  • Allcells LLC
  • American Type Culture Collection (ATCC)
  • Beike Biotechnology Co., Ltd.
  • BioTime, Inc.
  • Cellular Dynamics International
  • Corestem, Inc.
  • Gamida Cell Ltd.
  • HemaCare Corporation
  • Lifeline Cell Technology
  • Lonza Group Ltd.
  • Mesoblast Ltd.
  • Promocell GmbH
  • ReachBio LLC
  • Sanofi-aventis U.S. LLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Bone Marrow Transplant - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Blood Cancers Drives Demand for Bone Marrow Transplants
    • Advancements in Stem Cell Harvesting Techniques Propel Growth in Bone Marrow Transplant Procedures
    • Rising Success Rates and Improved Outcomes Strengthen Business Case for Bone Marrow Transplants
    • Expansion of Donor Registries and Matching Technologies Expands Addressable Market Opportunity
    • Growing Use of Cord Blood as a Stem Cell Source Drives Adoption of Bone Marrow Transplant Procedures
    • Technological Innovations in Immunosuppressive Treatments Propel Growth in Allogeneic Transplants
    • Rising Awareness and Education About Bone Marrow Donation Generate Increased Donor Participation
    • Challenges in Managing Graft-Versus-Host Disease (GVHD) Create Opportunities for Innovation in Post-Transplant Care
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bone Marrow Transplant Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bone Marrow Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Bone Marrow Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Bone Marrow Transplant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Myeloma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Thalassemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Autologous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Allogeneic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • JAPAN
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • CHINA
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • EUROPE
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Bone Marrow Transplant by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Bone Marrow Transplant by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Bone Marrow Transplant by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • FRANCE
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • GERMANY
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Bone Marrow Transplant by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Bone Marrow Transplant by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Bone Marrow Transplant by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • INDIA
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Bone Marrow Transplant by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Bone Marrow Transplant by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Bone Marrow Transplant by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Bone Marrow Transplant by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Bone Marrow Transplant by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Bone Marrow Transplant by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • AFRICA
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030

IV. COMPETITION